TGF-β treatment suppresses fibulin-1 mRNA expression and protein abundance, and fibulin-1 downregulation by TGF-β reduces the ability of human bone marrow stromal cells to induce prostate cancer cell death [131]. The gene discussed is FBLN1; the disease is prostate carcinoma.